drugset / Trial / NCT00499902
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-05
- Completion
- 2008-05
Outcome
Outcome not reported
Stopped: “CO Phase 2 data did not show sufficient improvement in cath opening at higher dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alfimeprase | Protein / enzyme biologic | 1 mg | Other |
| Subject | Alfimeprase | Protein / enzyme biologic | 5 mg | Other |
| Subject | Alfimeprase | Protein / enzyme biologic | 10 mg | Other |